Transglutaminase 2 expression in acute myeloid leukemia: Association with adhesion molecule expression and leukemic blast motility

Proteomics

Volumn 13, Issue 14, 2013, Pages 2216-2224

  Pierce, Andrew ^a   Whetton, Anthony D ^a   Meyer, Stefan ^a   Ravandi Kashani, Farhad ^b   Borthakur, Gautam ^b   Coombes, Kevin R ^b   Zhang, Nianxiang ^b   Kornblau, Steven ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; Biomedicine; Reverse phase protein array; Transglutaminase2

Indexed keywords

CELL ADHESION MOLECULE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL ADHESION; CELL MOTILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS;

ACUTE MYELOID LEUKEMIA; BIOMEDICINE; REVERSE PHASE PROTEIN ARRAY; TRANSGLUTAMINASE2;

ANALYSIS OF VARIANCE; BONE MARROW CELLS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; GTP-BINDING PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES; ONCOGENES; PROTEIN ARRAY ANALYSIS; PROTEIN INTERACTION MAPS; TRANSGLUTAMINASES; TUMOR CELLS, CULTURED;

EID: 84880643239     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201200471     Document Type: Article

References (26)

1. Kelly, L. M., Gilliland, D. G., Genetic's of myeloid leukemias. Annu. Rev. Genomics Hum. Genet. 2002, 3, 179-198.
2. Tefferi, A., Gilliland, D. G., Oncogenes in myeloproliferative disorders. Cell Cycle 2007, 6, 550-566.
3. Naujokat, C., Šarić, T., Concise review: role and function of the ubiquitin-proteasome system in mammalian stem and progenitor cells. Stem cells 2007, 25, 2408-2418.
4. Vink, J., Cloos, J., Kaspers, G. J. L., Proteasome inhibition as novel treatment strategy in leukaemia. Br. J. Haematol. 2006, 134, 253-262.
5. Williamson, A. J. K., Whetton, A. D., The requirement for proteomics to unravel stem cell regulatory mechanisms. J. Cell. Physiol. 2011, 226, 2478-2483.
6. Kornblau, S. M., Coombes, K. R., Use of reverse phase protein microarrays to study protein expression in leukemia: technical and methodological lessons learned. MethodsMol. Biol. 2011, 785, 141-155.
7. Kornblau, S. M., Qiu, Y. H., Zhang, N., Singh, N. et al., Abnormal expression of friend leukemia virus integration 1 protein is an adverse prognostic factor in acute myeloid leukemia. Blood 2011, 118, 5604-5612.
8. Kornblau, S. M., Tibes, R., Qiu, Y. H., Chen, W. et al., Functional proteomic profiling of AML predicts response and survival. Blood 2009, 113, 154-164.
9. Tibes, R., Qiu, Y., Lu, Y., Hennessy, B. et al., Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 2006, 5, 2512-2521.
10. Pierce, A., Unwin, R. D., Evans, C. A., Griffiths, S. et al., Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Mol. Cell. Proteomics 2008, 7, 853-863.
11. Fok, J. Y., Ekmekcioglu, S., Mehta, K., Implications of tissue transglutaminase expression in malignant melanoma. Mol. Cancer Ther. 2006, 5, 1493-1503.
12. Verma, A., Wang, H., Manavathi, B., Fok, J. Y. et al., Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res. 2006, 66, 10525-10533.
13. Yuan, L., Siegel, M., Choi, K., Khosla, C. et al., Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 2006, 26, 2563-2573.
14. Antonyak, M. A., Miller, A. M., Jansen, J. M., Boehm, J. E. et al., Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J. Biol. Chem. 2004, 279, 41461-41467.
15. Kumar, A., Xu, J., Brady, S., Gao, H. et al., Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One 2010, 5, e13390.
16. Mehta, K., Fok, J., Miller, F. R., Koul, D., Sahin, A. A., Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin. Cancer Res. 2004, 10, 8068-8076.
17. Jang, G. Y., Jeon, J. H., Cho, S. Y., Shin, D. M. et al., Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-[kappa]B activity in hypoxic tumor cells. Oncogene 2010, 29, 356-367.
18. Hwang, J. Y., Mangala, L. S., Fok, J. Y., Lin, Y. G. et al., Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008, 68, 5849-5858.
19. Akimov, S. S., Krylov, D., Fleischman, L. F., Belkin, A. M., Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J. Cell Biol. 2000, 148, 825-838.
20. Balajthy, Z., Csomós, K., Vámosi, G., Szántó, A. et al., Tissue-transglutaminase contributes to neutrophil granulocyte differentiation and functions. Blood 2006, 108, 2045-2054.
21. Csomós, K., Német, I., Fésüs, L., Balajthy, Z., Tissue transglutaminase contributes to the all-trans-retinoic acid-induced differentiation syndrome phenotype in the NB4 model of acute promyelocytic leukemia. Blood 2010, 116, 3933-3943.
22. Satpathy, M., Shao, M., Emerson, R., Donner, D. B., Matei, D., Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity. J. Biol. Chem. 2009, 284, 15390-15399.
23. Cao, L., Petrusca, D. N., Satpathy, M., Nakshatri, H. et al., Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis 2008, 29, 1893-1900.
24. Mangala, L. S., Fok, J. Y., Zorrilla-Calancha, I. R., Verma, A., Mehta, K., Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 2006, 26, 2459-2470.
25. Quere, R., Andradottir, S., Brun, A. C. M., Zubarev, R. A. et al., High levels of the adhesion molecule CD44 on leukemic cells generate acute myeloid leukemia relapse after withdrawal of the initial transforming event. Leukemia 2011, 25, 515-526.
26. Holland, M., Castro, F. V., Alexander, S., Smith, D. et al., RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia. Blood 2011, 118, 638-649.